Ginkgo biloba extract: Mechanisms and clinical indications

Archives of Physical Medicine and Rehabilitation

Volumn 81, Issue 5, 2000, Pages 668-678

  Diamond, Bruce J ^a,b,c   Shiflett, Samuel C ^b   Feiwel, Nancy ^a   Matheis, Robert J ^a   Noskin, Olga ^a   Richards, Jennifer A ^a   Schoenberger, Nancy E ^b  

^a KESSLER FOUNDATION   (United States)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^c WILLIAM PATERSON UNIVERSITY   (United States)

Author keywords

Aging; Dementia; EGb 761; Ginkgo biloba; Rehabilitation; Stroke; Traumatic brain injury

Indexed keywords

CP 202; GINKGO BILOBA EXTRACT; GINKGOLIDE;

AMNESIA; ANTIOXIDANT ACTIVITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPHEMA; MAJOR CLINICAL STUDY; META ANALYSIS; PHYTOTHERAPY; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME;

EID: 0034094018     PISSN: 00039993     EISSN: None     Source Type: Journal    
DOI: 10.1053/mr.2000.3840     Document Type: Review

References (120)

1. Chang JY, Chang MN. Medicinal uses of Ginkgo biloba. Today's Therapeutic Trends 1997;15.
2. DeFeudis FV. Ginkgo biloba extract (EGb 761): pharmacological activities and clinical applications. Paris: Elsevier; 1991.
3. Kleijnen J, Knipschild P. Ginkgo biloba. Lancet 1992;340: 1136-9.
4. Landes P. Market report: Whole Foods magazine's 2nd annual herb market survey for U.S. health food stores. HerbalGram 1997;40:52.
5. Blumenthal M, editor. The complete German commission E monographs: therapeutic guide to herbal medicines. Austin (TX): American Botanical Council; 1998.
6. Kleijnen J, Knipschild P. Ginkgo biloba for cerebral insufficiency. Br J Clin Pharmacol 1992;34:352-8.
7. Krauskopf R, Guinot P, Peetz HG. Long term on line EEG analyses demonstrating the pharmaco-dynamic effect of a defined Ginkgo biloba-extract. Karlsruhe, Germany: Beaufor-Schwabe International Report; 1983.
8. Luthringer R, d'Arbigny P, Macher JP. Ginkgo biloba extract (EGb 761), EEG and event-related potentials mapping profile. In: Christen Y, Courtois Y, Droy-Lefaix MT, editors. Advances in Ginkgo biloba extract research, Volume 4. Effects of Ginkgo biloba extract (EGb 761) on aging and age-related disorders. Paris: Elsevier; 1995. p. 107-18.
9. Subhan Z, Hindmarch I. The psychopharmacological effects of Ginkgo biloba extract in normal healthy volunteers. Intl J Clin Pharmacol Res 1984;4:89-93.
10. Schaffler K, Reeh P. Long-term drug administration effects of Ginkgo biloba on the performance of healthy subjects exposed to hypoxia. In: Agnoli A, Rapin JR, Scapagnini V, Weitbrecht WV, editors. Effects of Ginkgo biloba extract on organic cererbral impairment. London: John Libbey & Company, Ltd.; 1985. p. 77-84.
11. Schönhöfer PS, Schulte-Sasse H, Manhold C, Werner B. Sind Extrakte aus den Blättern des Ginkgobaumes bei peripheren Durchblutungs- und Himleistungsstörungen im Alter wirksam? Beurteilung von Tebonin und Rökan. Internistische Praxis 1989; 29:585-601.
12. Weiß H, Kallischnigg G. Ginkgo-biloba-Extrakt (EGb 761): Meta-analyse von Studien zum Nachweis der therapeutischen Wirksamkeit bei Hirnleistungsstörungen bzw. peripherer arterieller VerschluBkrankheit. Münch Med Wochenschr 1991;133:138-42.
13. Kanowski S, Herrmann WM, Stephan K, Wierich W, Horr R. Proof of efficacy of the Ginkgo biloba special extract EGB 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. Pharmacopsychiatry 1996;29:47-56.
14. Hofferberth B. [The effect of Ginkgo biloba extract on neurophysiological and psychometric measurement results in patients with psychotic organic brain syndrome. A double-blind study against placebo] [German]. Arzneimittelforschung 1989;39:918-22.
15. Rai GS, Shovlin C, Wesnes KA. A double-blind, placebo controlled study of Ginkgo biloba extract ('Tanakan') in elderly outpatients with mild to moderate memory impairment. Curr Med Res Opin 1991;12:350-5.
16. Geßner B, Voelp A, Klasser M. Study of the long term action of a Ginkgo biloba extract on vigilance and mental performance as determined by means of quantitative pharmaco-EEG and psychometric measurements. Arzneimittelforschung 1985;35:1459-65.
17. Itil T, Martorano D. Natural substances in psychiatry (Ginkgo biloba in dementia). Psychopharmacol Bull 1995;31:147-58.
18. Eckmann F, Schlag H. Kontrollierte Doppelbind-Studie zum Wirksamkeitsnachweis von Tebonin forte bei Patienten mit zerebrovaskulärer Insuffizienz. Fortschr Med 1982;100:1474-8.
19. Eckmann F. [Cerebral insufficiency - treatment with Gingko biloba extract. Time of onset in a double-blind study with 60 patients] [German]. Fortschr Med 1990;29:557-60.
20. Schubert H, Halama P. [Depressive episode primarily unresponsive to therapy in elderly patients: efficacy of Ginkgo biloba extract EGb 761 in combination with antidepressants] [German]. Geriatrie Forschung 1993;1:45-53.
21. Halama P. [Ginkgo biloba: effectiveness of a special extract in patients with cerebral insufficiency] [German]. Munch Med Wochenschr 1991;133:190-4.
22. Arrigo A, Cattaneo S. Clinical and psychometric evaluation of Ginkgo biloba extract in chronic cerebrovascular diseases. In: Agnoli A, Rapin JR, Scapagnini V, Weitbrecht WV, editors. Effects of Ginkgo biloba extract on organic cerebral impairment. London: John Libbey & Company, Ltd; 1985. p. 85-90.
23. Wesnes K, Simmons D, Rook M, Simpson P. A double-blind placebo-controlled trial of Tanakan in the treatment of idiopathic cognitive impairment in elderly. Hum Psychopharmacol 1987;2: 159-69.
24. Le Bars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF. A placebo-controlled, double-blind, randomized trial of an extract of Gingko biloba for dementia. JAMA 1997;278:1327-32.
25. Qizilbash N, Whitehead A, Higgins J, Wilcock G, Schneider L, Farlow M. Cholinesterase inhibition for Alzheimer's disease: a meta-analysis of the tacrine trials. Dementia Trialist's Collaboration. JAMA 1998;280:1777-82.
26. Gerhardt G, Rogalla K, Jaeger J. [Drug therapy of disorders of cerebral performance. Randomized comparative study of dihydroergotoxine and Ginkgo biloba extract] [German]. Fortschr Med 1990;108:384-8.
27. Hartmann A, Frick M. [Effectiveness of a Ginkgo special extact on psychometric parameters in patients with vascular dementia]. Münch Med Wochenschr 1991;133:S23-5.
28. Allain H, Raoul P, Lieury A, LeCoz F, Gandon J-M, d'Arbigny P. Effect of two doses of Ginkgo biloba extract (EGb 761) on the dual-coding test in elderly subjects. Clin Ther 1993;15:549-58.
29. Hofferberth B. The efficacy of EGb 761 in patients with senile demential of the Alzheimer type: a double-blind, placebo-controlled study on different levels of investigation. Hum Psycho-pharmacol 1994;9:215-22.
30. Polich J. EEG and ERP assessment of normal aging. Electroencephalogr Clin Neurophysiol 1997;104:244-56.
31. Maier-Hauff K. LI 1370 nach zerebraler Aneurysma-Operation. Münch Med Wochenschr 1991;133:S34-7.
32. Hamann KF. Physikalische Therapie des vestibulären Schwindels in Verbindung mit Ginkgo-biloba-Extrakt. Therapiewoche 1985; 35:4586-90.
33. Schwerdtfeger F. Elektronystagmographisch und klinisch dokumentierte: Therapieerfahrungen mit rokän® bei Schwindelsymptomatik. Therapiewoche 1981;31:8658-67.
34. Hofferberth B. [Ginkgo biloba special extract in patients with psychotic organic brain syndrome] [German]. Munch Med Wochenschr 1991;133:S30-S33.
35. Brüchen E, Heinrich SE, Ruf-Kohler P. [Efficacy of LI 1370 in elderly patients with cerebral insufficiency: multicentric double-blind trial] [German]. Münch Med Wochenschr 1991;133: S9-14.
36. Brailowsky S, Montiel T, Hernandez-Echeagarray E, Flores-Hernandez J, Hernandez-Pineda R. Effects of Ginkgo biloba extract on cortical hemiplegia in the rat. In: Christen Y, Costentin J, Lacour M, editors. Effects of Ginkgo biloba extract (EGb 761) on the central nervous system. Paris: Elsevier; 1992. p. 95-103.
37. Mancini M, Agozzino B, Bompani R. Clinical and therapeutic effects of Ginkgo biloba extract (GBE) versus placebo in the treatment of psychorganic senile demential or arteriosclerotic origin. Gazz Med Ital Arch Sci Med 1993;152:69-80.
38. Letzel H, Haan J, Feil WB. Nootropics: efficacy and tolerability of products from three active substance classes. J Drug Dev Clin Pract 1996;8:77-94.
39. Rosenblatt M, Mindel J. Spontaneous hyphema associated with ingestion of Ginkgo biloba extract [letter]. N Engl J Med 1997;336:1108.
40. Rowin J, Lewis SL. Spontaneous bilateral subdural hematomas associated with chronic Ginkgo biloba ingestion. Neurology 1996;46:1775-6.
41. Gilbert GJ. Ginkgo biloba [letter; comment]. Neurology 1997;48: 1137.
42. Vale S. Subarachnoid haemorrhage associated with Ginkgo biloba [letter]. Lancet 1998;352:36.
43. Gianni LM, Dreitlein WB. Some popular OTC herbals can interact with anticoagulant therapy. US Pharmacist 1998;23:80,83-84,86.
44. Jaggy J, Koch E. Chemistry and biology of alkylphenols from Ginkgo biloba leaves. Pharmazie 1997;52:735-8.
45. DeFeudis FV. From chemistry to clinic. Wiesbaden, Germany: Ullstoin Medical; 1998.
46. Li CL, Wong YY. The bioavailability of ginkgolides and Ginkgo biloba extracts. Planta Med 1997;63:563-5.
47. Moreau JP, Eck CR, McCabe J, Skinner S. Absorption, distribution, and excretion of tagged Ginkgo biloba leaf extract in the rat. In: Fünfgeld EW, editor. Rökan, Ginkgo biloba: recent results in pharmacology and clinic. Berlin: Springer-Verlag; 1988. p. 37-45.
48. Nieder M. Pharmacokinetic der Ginkgo-Flavonole in plasma. Münch Med Wochenschr 1991;(Suppl 1):S61-2.
49. Auguet M, Clostre F. Effects of an extract of Ginkgo biloba and diverse substances on the phasic and tonic components of the contraction of an isolated rabbit aorta. Gen Pharmacol 1983;14: 277-80.
50. Hellegouarch A, Baranès J, Clostre F, Drieu K, Braquet P, DeFeudis FV. Comparison of the contractile effects on an extract of Ginkgo biloba and some neurotransmitters on rabbit isolated vena cava. Gen Pharmacol 1985;16:129-32.
51. Reuse-Blom S, Drieu K. Effects of Ginkgo biloba extract on arteriolar spasm in rabbits. In: Fünfgeld EW, editor. Rökan, Ginkgo biloba: recent results in pharmacology and clinic. Berlin: Springer-Verlag; 1988. p. 162-8.
52. Borchardt RT, Huber JA. Catechol-O-methyltransferase-5 structure activity relationships for inhibition by flavonoids. J Med Chem 1975;3:59-62.
53. White HL. Extracts of Ginkgo biloba leaves inhibit monoamine oxidase. Life Sci 1996;58:1315-21.
54. Chatterjee SS. Effects of Ginkgo biloba extract on cerebral metabolic processes. In: Agnoli A, Rapin JR, Scapagnini V, Weitbrech WV, Eds. Effects of Ginkgo biloba extract on organic cerebral impairment. London: John Libbey; 1985. p. 5-14.
55. Peter H, Fisel J, Weisser W. [On the pharmacology of the active ingredients of Ginkgo biloba] [German]. Arzneimttelforschung 1966;16:719-25.
56. Kobuchi H, Droy-Lefaix MT, Christen Y, Packer L. Ginkgo biloba extract (EGb 761): Inhibitory effect on nitric oxide production in the macrophage cell line RAW 264.7. Biochem Pharmacol 1997;53:897-903.
57. Barth SA, Inselmann G, Heidemann HT. Influences of Ginkgo biloba on cyclosporin A induced lipid peroxidation in human liver microsomes in comparison to vitamin E, glutathion and N-acetylcysteine. Biochem Pharmacol 1991;41:1521-6.
58. Bruel A, Gardette J, Berrou E, Droy-Lefaix MT, Picard J. Effects of Ginkgo biloba extract on glucose transport and glycogen synthesis of cultured smooth muscle cells from pig aorta. Pharmacol Res 1989;21:421-9.
59. Janssens D, Michiels C, Delaive E, Eliaers F, Drieu K, Remade J. Protection of hypoxia-induced ATP decrease in endothelial cells by Ginkgo biloba extract and bilobalide. Biochem Pharmacol 1995;50:991-9.
60. Coeffler E. PAF-acether analogs, platelet activation an BN 52021. In: Braquet P, editor. Ginkgolide. Barcelona: JR Prous; 1988. p. 105-13.
61. Braquet P, Paubert-Braquet M, Koltai M, Bourgain R, Bussolino F, Hosford D. Is there a case for PAF antagonists in the treatment of ischemic disease? Trends Pharmacol Sci 1989;10:23-30.
62. Spinnewyn B, Blavet N, Clostre F, Bazan N, Braquet P. Involvement of platelet-activating factor (PAF) in cerebral post-ischemic phase in mongolian gerbils. Prostaglandins 1987;34:337-49.
63. Marcocci L, Maguire JJ, Droy-Lefaix MT, Packer L. The nitric oxide-scavenging properties of Ginkgo biloba extract EGb 761. Biochem Biophys Res Comm 1994;201:748-55.
64. Pincemail J, Deby C. The antiradical properties of Ginkgo biloba extract. In: Fünfgeld EW, editor. Rökan, Ginkgo biloba: recent results in pharmacology and clinic. Berlin: Springer-Verlag; 1988. p. 71-80.
65. Robak J, Gryglewski RJ. Flavonoids are scavengers of superoxide anions. Biochem Pharmacol 1988;37:837-41.
66. Gryglewski RJ, Korbut R, Robak J, Sweiss J. On the mechanism of antithrombotic action of flavonoids. Biochem Pharmacol 1987;36:317-22.
67. Yan L-J, Droy-Lefaix MT, Packer L. Ginkgo biloba extract (EGb 761) protects human low density lipoproteins against oxidative modification mediated by copper. Biochem Biophys Res Comm 1995;212:360-6.
68. Braquet P, Esanu A, Buisine E, Hosford D, Broquet C, Koltai M. Recent progress in ginkgolide research. Medicinal Res Rev 1991;11:295-355.
69. Braquet P, Braquet M, Deby C. Oxidative damages induced by cerebral ischemia: Protective role of some radical scavenger related drugs. J Cereb Blood Flow Metab 1983;Suppl:1564-5.
70. Ni Y, Zhao B, Hou J, Xin W. Preventitive effect of Ginkgo biloba extract on apoptosis in rat cerebellar neuronal cells induced by hydroxyl radicals. Neurosci Lett 1996;214:115-8.
71. Rancurel G, Raynaud C, Cahn J. Effects of Ginkgo biloba extract on Xenon 133 CBF and I 123 iodo-amphetamine distribution in human brain acute infarction: A preliminary study. In: Agnoli A, Rapin JR, Scapagnini V, Weitbrecht WV, editors. Effects of Ginkgo biloba extract on organic cerebral impairment. London: John Libbey & Company, Ltd.; 1985. p. 101-6.
72. Krieglstein J, Beck T, Seibert A. Influence of an extract of Ginkgo biloba on cerebral blood flow and metabolism. Life Sci 1986;39: 2327-34.
73. Oberpichler J, Beck T, Abdel-Rahman MM, Bielenberg GW, Krieglstein J. Effects of Ginkgo biloba constituents related to protection against brain damage caused by hypoxia. Pharmacol Res Comm 1988;20:349-68.
74. Oberpichler H, Sauer D, Rossberg C, Mennel HD, Krieglstein J. PAF antagonist ginkgolide B reduces postischemic neuronal damage in rat brain hippocampus. J Cereb Blood Flow Metab 1990;10:133-5.
75. Brunello N, Racagni G, Clostre F, Drieu K, Braquet P. Effects of an extract of Ginkgo biloba on noradrenergic systems of rat cerebral cortex. Pharmacol Res Comm 1985;17:1063-72.
76. 2-Adrenoceptor changes during cerebral aging. The effect of Ginkgo biloba extract. J Pharm Pharmacol 1992;44:24-7.
77. Racagni G, Brunello N, Paoletti R. Variations in neuromediators in cerebral aging: effect of Ginkgo biloba extract. In: Fünfgeld EW, editor. Rökan, Ginkgo biloba: recent results in pharmacology and clinic. Berlin: Springer-Verlag; 1988. p. 98-102.
78. 3H]PAF platelet-activating factor (PAF) to platelet membranes. In: Braquet P, editor. Ginkgolides, Vol 1. Barcelona: JR Prous; 1988. p. 79-84.
79. Ramassamy C, Christen Y, Clostre F, Costentin J. The Ginkgo biloba extract, EGb 761, increases synaptosomal uptake of 5-hydroxytryptamine: in-vitro and ex-vivo studies. J Pharm Pharmacol 1992;44:943-5.
80. Taylor JE. Binding of neuromediators to their receptors in rat brain: effect of chronic administration of Ginkgo biloba extract. In: Fünfgeld EW, editor. Rökan, Ginkgo biloba: recent results in pharmacology and clinic. Berlin: Springer-Verlag; 1988. p. 103-8.
81. Le Poncin-Lafitte M, Rapin J, Rapin JR. Effects of Ginkgo biloba on changes induced by quantitative cerebral microembolization in rats. Arch Int Pharmacodyn Ther 1980;243:236-44.
82. Ramassamy C, Clostre F, Christen Y, Costentin J. Prevention by a Ginkgo biloba extract (GBE 761) of the dopaminergic neurotoxicity of MPTP. J Pharm Pharmacol 1990;42:785-9.
83. Amri H, Ogwuegbu SO, Boujrad N, Drieu K, Papadopoulos V. In vivo regulation of the peripheral-type benzodiazepine receptor and glucocorticoid synthesis by Ginkgo biloba extract Egb 761 and isolated ginkgolides. Endocrinology 1996;137:5707-17.
84. Halama P, Bartsch G, Meng G. [Disorders of brain performance of vascular origin. Randomized double-blind study of the effectiveness of Ginkgo biloba extract] [German]. Fortschr Der Med 1988;106:408-12.
85. Attella MJ, Hoffman SW, Stasio MJ, Stein DG. Ginkgo biloba extract facilitates recovery from penetrating brain injury in adult male rats. Exp Neurol 1989;105:62-71.
86. Stein DG, Hoffman SW. Chronic administratin of Ginkgo biloba extract (EGb 761) can enhance recovery from traumatic brain injury. In: Christen Y, Costentin J, Lacour M, editors. Effects of Ginkgo biloba extract (EGb 761) on the central nervous system. Paris: Elsevier; 1992. p. 95-103.
87. Taillandier J, Ammar A, Rabourdin JP, Ribeyre JPPJ, Niddam S, Peirart H. [Treatment of cerebral aging disorders with Ginkgo biloba extract. A longitudinal multicenter double-blind drug vs. placebo study] [French]. Presse Méd 1986;15:1583-7.
88. Weitbrecht WU, Jansen W. [Primary degenerative dementia: therapy with Ginkgo biloba extract. Placebo-controlled double-blind and comparative study] [German]. Fortschr Med 1986;104: 199-202.
89. Meyer B. [A multicenter study of tinnitus. Epidemiology and therapy] [French]. Ann Otolaryngol Chir Cervicofac 1986;103: 185-8.
90. Meyer B. A multicenter randomized double-blind study of Ginkgo biloba extract versus placebo in the treatment of tinnitus. In: Fünfgeld EW, editor. Rökan, Ginkgo biloba: recent results in pharmacology and clinic. Berlin: Springer-Verlag; 1988. p. 245-50.
91. Sohn M, Sikora R. Ginkgo biloba extract in the therapy of erectile dysfunction. J Sex Ed Ther 1991;17:53-61.
92. Bartlik B, Kogan R. Novel remedies for antidepressant-induced sexual dysfunction. Presented at the 13th World Congress of Sexology; June 1997; Valencia, Spain.
93. Lebuisson DA, Leroy L, Rigal G. [Treatment of senile macular degeneration with Ginkgo biloba extract. A preliminary double-blind drug vs. placebo study] [French]. Presse Med 1986;15: 1556-8.
94. Doly M, Droy-Lefaix MT. Lipid peroxidation in the pathology of the retina. In: Packer I, Prilipko I, Christen Y, editors. Free radicals in the brain - aging, neurological and mental disorders. Berlin: Springer-Verlag; 1992. p. 23-39.
95. Cohen A. Treatment of antidepressant-induced sexual dysfunction with Ginkgo biloba extract. Presented at the American Psychiatric Association Annual Meeting; 1996; New York.
96. Borzeix MG. Effects of Ginkgo biloba extract on two types of cerebral edema. Agnoli A, Rapin JR, Scapagnini V, Weitbrecht WV, editors. Effects of Ginkgo biloba extract on organic cerebral impairment. London: John Libbey & Company, Ltd; 1985. p. 51-6.
97. Hofferberth B. Simultanerfassung elektrophysiologischer, psychometrischer und rheologischer Parameter bei Patienten mit hirnorganischem Psychosyndrom und erhöhtem Gefäßrisiko - Eine Placebo-kontrollierte Doppelblind-studie mit Ginkgo biloba-Extrakt EGB 761. In: Stodtmeister R, Pillunat LE, editors. Mikrozirkulation in Gehirn Und Sinnesorganen. Stuttgart: Enke Verlag; 1991. p. 64-74.
98. Gräßel E. [Effect of Ginkgo-biloba extract on mental performance. Double-blind study using computerized measurment conditions in patients with cerebral insufficiency]. Fortschr Med 1992;110:73-6.
99. Israël L, Dell'accio E, Martin G, Hugonot R. [Ginkgo biloba extract and memory training programs. Comparative assessment on elderly outpatients living in the community] [French]. Psychol Méd 1987;19:1431-9.
100. Blumenthal M, editor. The complete German Commission I monographs: therapeutic guide to herbal medicines. Austin (TX): American Botanical Council; 1998.
101. 1A receptors during aging: reversal by Ginkgo biloba extract (EGb 761). J Pharm Pharmacol 1994;46:316-8.
102. Physician's Desk Reference (PDR) for Herbal Medicines. 1st ed. Montvale (NJ): Medical Economics Company; 1998.
103. Galley P, Safi N. Tanakan et cerveau senile, Etude radiocirculographique. Bordeaux Med 1977;10:171-6.
104. Gessner B, Voelp A, Klasser M. Study of the long term action of a Ginkgo biloba extract on vigilance and mental performance as determined by means of quantitative pharmaco-EEG and psychometric measurements. Arzneimittelforschung 1985;35:1459-65.
105. Deberdt W. Interaction between psychological and pharmacological treatment in cognitive impairment. Life Sci 1994;55:2057-66.
106. Haan J, Reckermann U, Welter FL, Sabin G, Müller E. Ginkgo-biloba-Flavonglykoside: Therapiemöglichkeit der zerebralen Insuffizienz. Med Welt 1982;33:1001-5.
107. Schmidt U, Rabinovici K, Lande S. [Effect of a Ginkgo biloba special extract on well-being in cerebral insufficiency] [German]. Münch Med Wochenschr 1991;133:S15-8.
108. Taillandier J, Ammar A, Rabourdin JP, Ribeyre JPPJ, Niddam S, Peirart H. Ginkgo biloba extract in the treatment of cerebral disorders due to aging: Longitudinal, multicenter, double-blind study versus placebo. In: Fünfgeld EW, editor. Rökan, Ginkgo biloba: recent results in pharmacology and clinic. Berlin: Springer-Verlag; 1988. p. 291-301.
109. Vorberg G. Ginkgo biloba extract (GBE): a long-term study of chronic cerebral insufficiency in geriatric patients. Clin Trials J 1985;22:149-57.
110. Artieres J. Effects therapeutiques du Tanakan sur les hypoacousies et les acouphenes. Lyon Mediterr Med 1978;14:2503-15.
111. Allard M. Treatment of old age disorders with Ginkgo biloba extract. In: Fünfgeld EW, editor. Rökan, Ginkgo biloba: recent results in pharmacology and clinic. Berlin: Springer-Verlag; 1988. p. 201-11.
112. Augustin P. Le Tanakan en gériatrie: étude clinique et psychométrique chez 189 malades d'hospice. Psychol Méd 1976;8: 123-30.
113. Cahn J. Effects of Ginkgo biloba extract (GBE) on the acute phase of cerebral ischemia due to embolisms. In: Agnoli A, Rapin JR, Scapagnini V, Weitbrecht WV, editors. Effects of Ginkgo biloba extract on organic cerebral impairment. London: John Libbey & Company, Ltd.; 1985. p. 43-50.
114. Chatterjee SS, Gabard B. Protective effects of an extract of Ginkgo biloba and other hydroxyl radical scavengers against hypoxia. Presented at the Eighth International Congress of Pharmacology; 1981 Jul 19-24; Tokyo.
115. Krieglstein J. Marburg. Neuroprotectic properties of Ginkgo biloba constituents. Zeitschr Fur Phytother 1994;15:92-6.
116. Panetta T, Marcheselli VL, Braquet P, Spinnewyn B, Bazan NG. Effects of a platelet activating factor antagonist (BN52021) on free fatty acids, diacylglycerols, polyphosphoinositides and blood flow in the gerbil brain: inhibition of ischemia-reperfusion induced cerbral ischemia. Biochem Biophy Res 1987;149:580-7.
117. 2+-loaded brain neurons. Brain Res 1994;635:125-9.
118. Spinnewyn B, Blavet N, Clostre F. Effects of Ginkgo biloba extract on a cerebral ischemia model in gerbils. In: Fünfgeld EW, editor. Rökan, Ginkgo biloba: recent results in pharmacology and clinic. Berlin: Springer-Verlag; 1988. p. 143-52.
119. Karcher L, Zagermann P, Krieglstein J. Effect of an extract of Ginkgo biloba on rat brain energy metabolism in hypoxia. NaunynSchmiedebergs Arch Pharmacol 1984;327:31-35.
120. Chabrier PE, Roubert P. Effect of Ginkgo biloba extract on the blood-brain barrier. In: Fünfgeld EW, editor. Rökan, Ginkgo biloba: recent results in pharmacology and clinic. Berlin: Springer-Verlag; 1988. p. 117-25.